Results 151 to 160 of about 6,019,041 (305)

Proton beam therapy in paediatric cancer: Anticipating the opening of the Australian Bragg Centre for Proton Therapy and Research

Journal of Medical Imaging and Radiation Oncology, EarlyView., 2023
Summary Proton Beam Therapy (PBT) has the potential to improve paediatric cancer care by reducing radiation exposure and thus long‐term toxicities. Ethical concerns and debates surrounding the treatment, such as eligibility and accessibility, are ongoing in Australia. The Australian Bragg Centre for Proton Therapy and Research (ABCPTR) (named after Sir
Jeremy Khong, Hui Tee, Peter Gorayski, Hien Le, Michael Penniment, Sophie Jessop, Jordan Hansford, Melanie Penfold, Julia Green, Kelly Skelton, Frank Saran   +10 more
wiley   +1 more source

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy

EJC Skin Cancer
K. Kisielewska, K. Kozak, P. Teterycz, Ł. Galus, J. Mackiewicz, P. Brandys, B. Cybulska-Stopa, N. Kempa-Kamińska, M. Ziętek, J. Żubrowska, R. Dziura, P. Sobczuk, A.M. Czarnecka, P. Rutkowski   +13 more
doaj   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

International Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus   +10 more
wiley   +1 more source

Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts. [PDF]

Cancer Res Commun
Gorgels D, Wang CC, De Cock L, De Sutter L, Wyns K, Verbeeck K, Vanleeuw U, Hompes D, Sinnaeve F, Wafa H, Guillén MJ, Avilés P, Sciot R, Wozniak A, Schöffski P.   +14 more
europepmc   +1 more source

Early Postoperative Adverse Events (≤ 30 Days) in Spinal Oncology: Defining the Incidence, Severity, and Predictors in a Mixed Prospective Cohort Including Intradural and Metastatic Spinal Tumors

International Journal of Cancer, EarlyView.
ABSTRACT Complication reporting in spinal tumor surgery remains inconsistently defined. We aimed to quantify the incidence, severity, and spectrum of early (≤ 30 days) postoperative adverse events (AEs) in spinal tumor surgery and to identify predictors of overall and serious complications using standardized severity grading.
Meltem Ivren, Philip Dao Trong, Maximilian Klass, Martin Dugas, Sebastian Ille, Sandro M. Krieg, Pavlina Lenga   +6 more
wiley   +1 more source

Pediatric sarcomas: challenges and opportunities. [PDF]

Genes Dev
Gao Y, Bailey KM, Blackman SC, Bushweller JH, Chong S, DeHond K, Grembecka J, Hatley ME, Kadoch C, Koehler AN, Linardic CM, Renna P, Reu FJ, Rivera MN, Stewart EA, Stillman B, Sweet-Cordero EA, Stegmaier K, Vakoc CR, Guenther LM.   +19 more
europepmc   +1 more source

Non–AIDS‐Defining Cancer Incidence in People With HIV in Milan, Italy, 2000–2023: Temporal Trends and Comparison With the General Population

International Journal of Cancer, EarlyView.
ABSTRACT People with HIV (PWH) are living longer, but contemporary data on non–AIDS‐defining cancers (NADCs) in Italy remain limited. We assessed incident cancers in a retrospective cohort of PWH in Milan, Italy, between January 2000 and December 2023. Follow‐up was grouped into 2000–2007, 2008–2015, and 2016–2023. Incidence rates (IRs) were calculated
Giacomo Pozza, Maddalena Matone, Letizia Oreni, Giorgia Carrozzo, Beatrice Caloni, Maria Vittoria Cossu, Davide Moschese, Anna Lisa Ridolfo, Cristina Gervasoni, Cinzia Fasola, Nicla La Verde, Davide Dalu, Spinello Antinori, Andrea Gori, Andrea Giacomelli   +14 more
wiley   +1 more source

Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review. [PDF]

Explor Target Antitumor Ther
Yarar S, Tsagkozis P.
europepmc   +1 more source

Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

International Journal of Cancer, EarlyView.
ABSTRACT Approximately 6%–8% of children and adolescents with rhabdomyosarcoma (RMS) have an underlying cancer predisposition disorder (CPD), which varies between embryonal and alveolar subtypes and other clinical characteristics. Identifying a CPD remains challenging, as traditional approaches rely on clinical features and family history. Additionally,
Taylor M. Luckie, Sarah Scollon, Yao Yu, Aniko Sabo, Tiffany Chambers, Olga Taylor, Logan G. Spector, Michael E. Scheurer, Douglas S. Hawkins, Rajkumar Venkatramani, Chad D. Huff, Sharon E. Plon, Philip J. Lupo   +12 more
wiley   +1 more source

Robotic-assisted compartmental dissection for retroperitoneal sarcoma: a feasibility study on cadavers with the da Vinci Xi system. [PDF]

J Robot Surg
Wakker J, Ohlde A, van Rüth V, Schewe S, Melling N, Nickel F, Mann O, Hackert T, Spindler V, Kurmann S, Berndt R, Albertsmeier M, Jakob J, Duprée A.   +13 more
europepmc   +1 more source